Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States (original) (raw)

Abstract

Purpose

Based on current practice guidelines, there are a substantial number of individuals who do not meet criteria for chronic hepatitis B (CHB) treatment eligibility but may be at risk of developing HCC. We sought to determine the estimated number of untreated patients with CHB in the Gray Zone or immune-tolerant phase who would develop HCC.

Methods

US epidemiologic data were obtained from the US Department of HHS. The literature was reviewed for studies that analyzed the distribution of phases of CHB patients including the Gray Zone and studies that determined the cumulative incidence of HCC over a set period unique to both the Gray Zone and the immune-tolerant phase populations. We modeled the projected number of patients in each group who would develop HCC in a period of 5 and 10 years.

Results

There are about 880,000 to 1.89 million people living with CHB in the US. Based on our model, we estimated 1224–4146 patients and 6662–22,574 patients will likely develop HCC in 5 years and 10 years, respectively, if left untreated in the high viral load and normal liver enzyme Gray Zone. An estimated 356–1537 patients and 873–3774 patients will develop HCC in 5 years and 10 years, respectively, if left untreated in the immune-tolerant phase of CHB. Among patients who develop cirrhosis in the Gray Zone, approximately, 1615–5471 patients will develop HCC.

Conclusion

Current guidelines do not recommend hepatitis B antiviral therapy in patients in the Gray Zone and the immune-tolerant phase. Patients who fall into these categories are still at risk for HCC. By the numbers, the projected number of patients to develop HCC among these populations is in the order of thousands. Future guidelines should explore increasing treatment eligibility for potential mitigation of HCC burden in the US.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Data Availability

No datasets were generated or analyzed during the current study.

References

  1. WHO. IARC Monographs on the Identification of Carcinogenic Hazards to Humans WHO. https://monographs.iarc.who.int/list-of-classifications. Accessed 2024
  2. Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12:84. https://doi.org/10.1186/s40364-024-00611-y.
    Article PubMed PubMed Central Google Scholar
  3. Lim YS, Kim WR, Dieterich D et al. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses. 2023. https://doi.org/10.3390/v15040997.
    Article PubMed PubMed Central Google Scholar
  4. Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12:33–34. https://doi.org/10.1002/cld.728.
    Article PubMed PubMed Central Google Scholar
  5. European Association for the Study of the Liver, Electronic address EEE, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398. https://doi.org/10.1016/j.jhep.2017.03.021.
    Article Google Scholar
  6. Sarin SK, Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. https://doi.org/10.1007/s12072-015-9675-4.
    Article CAS PubMed Google Scholar
  7. Mak LY, Yee LJ, Wong RJ, Ramers CB, Frenette C, Hsu YC. Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase. J Viral Hepat. 2024. https://doi.org/10.1111/jvh.13914.
    Article PubMed PubMed Central Google Scholar
  8. Yao K, Liu J, Wang J et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28:1025–1033. https://doi.org/10.1111/jvh.13511.
    Article CAS PubMed Google Scholar
  9. Huang DQ, Li X, Le MH et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol. 2022;20:1803-1812 e5. https://doi.org/10.1016/j.cgh.2021.01.019.
    Article CAS PubMed Google Scholar
  10. Huang DQ, Tran A, Yeh ML et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78:1558–1568. https://doi.org/10.1097/HEP.0000000000000459.
    Article PubMed Google Scholar
  11. Lim YS. Gray zone of hepatitis B virus infection. Saudi J Gastroenterol. 2024;30:76–82. https://doi.org/10.4103/sjg.sjg_279_23.
    Article PubMed Google Scholar
  12. Hui CK, Leung N, Yuen ST et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395–401. https://doi.org/10.1002/hep.21724.
    Article PubMed Google Scholar
  13. Duan M, Xiao H, Shi M et al. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT. BMC Infect Dis. 2024;24:723. https://doi.org/10.1186/s12879-024-09617-1.
    Article CAS PubMed PubMed Central Google Scholar
  14. Lin MH, Li HQ, Zhu L et al. Liver fibrosis in the natural course of chronic hepatitis B viral infection: a systematic review with meta-analysis. Dig Dis Sci. 2022;67:2608–2626. https://doi.org/10.1007/s10620-021-07009-y.
    Article CAS PubMed Google Scholar
  15. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. https://doi.org/10.1001/jama.295.1.65.
    Article CAS PubMed Google Scholar
  16. HHS. Hepatitis B Basic Information. https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/hepatitis-b-basics/index.html#:~:text=for%20possible%20treatment.-,How%20Many%20People%20Have%20Hepatitis%20B?,to%20the%20World%20Health%20Organization%20. Accessed 14 Sep 2024
  17. CDC. Clinical Overview of Hepatitis B. CDC. https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/index.html#:~:text=Long%2Dterm%20effects&text=Acute%20hepatitis%20B%20is%20a%20short%2Dterm%20illness%20that%20is,with%20no%20lasting%20liver%20damage. Accessed 13 Oct 2024
  18. Gan QY, Wang JX, Qian F et al. Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2023;30:803–809. https://doi.org/10.1111/jvh.13873.
    Article CAS PubMed Google Scholar
  19. Lee HA, Kim SU, Seo YS, Ahn SH, Rim CH. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun. 2023;7:e0011. https://doi.org/10.1097/HC9.0000000000000011.
    Article PubMed PubMed Central Google Scholar
  20. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50. https://doi.org/10.1053/j.gastro.2004.09.014.
    Article PubMed Google Scholar
  21. Yip TC, Wong GL, Wong VW. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Clin Mol Hepatol. 2021;27:273–277. https://doi.org/10.3350/cmh.2021.0019.
    Article PubMed PubMed Central Google Scholar
  22. Kim GA, Lim YS, Han S et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945–952. https://doi.org/10.1136/gutjnl-2017-314904.
    Article CAS PubMed Google Scholar
  23. Jeon MY, Kim BK, Lee JS et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clin Mol Hepatol. 2021;27:295–304. https://doi.org/10.3350/cmh.2020.0216.
    Article PubMed Google Scholar
  24. Lee HA, Lee HW, Kim IH et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196–204. https://doi.org/10.1111/apt.15741.
    Article CAS PubMed Google Scholar
  25. Lee HW, Kim SU, Baatarkhuu O et al. Comparison between chronic hepatitis B patients with untreated immunetolerant phase vs those with virological response by antivirals. Sci Rep UK. 2019. https://doi.org/10.1038/s41598-019-53776-0.
    Article Google Scholar
  26. Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol. 2015;13:193-201 e1. https://doi.org/10.1016/j.cgh.2014.07.019.
    Article PubMed Google Scholar
  27. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797–816. https://doi.org/10.1016/j.cld.2007.08.005.
    Article PubMed Google Scholar
  28. Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51:1169–1179. https://doi.org/10.1111/apt.15725.
    Article CAS PubMed Google Scholar
  29. WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. https://www.who.int/publications/i/item/9789240090903. Accessed 14 Sep 2024
  30. Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022. https://doi.org/10.1172/JCI154833.
    Article PubMed PubMed Central Google Scholar
  31. Choi WM, Yip TC, Kim WR et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients. Hepatology. 2024;80:428–439. https://doi.org/10.1097/HEP.0000000000000752.
    Article PubMed Google Scholar
  32. Choi WM, Kim GA, Choi J et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024;73:649–658. https://doi.org/10.1136/gutjnl-2023-330225.
    Article CAS PubMed Google Scholar
  33. Choi WM, Yip TC, Wong GL et al. Baseline viral load and on-treatment hepatocellular carcinoma risk in chronic hepatitis B: a multinational cohort study. Clin Gastroenterol Hepatol. 2024. https://doi.org/10.1016/j.cgh.2024.07.031.
    Article PubMed Google Scholar
  34. Che-To Lai J, Wong GLH, Tse YK, Hui VWK, Sze-Man Lai M, Chan HLY, Wong VWS, Yip TCF. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis. J Hepatol. 2024. https://doi.org/10.1016/j.jhep.2024.11.018.
    Article PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Kevin Pak & Ryan Sachar
  2. Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Sammy Saab

Authors

  1. Kevin Pak
  2. Ryan Sachar
  3. Sammy Saab

Contributions

Role in the Study: Study concept and design (SS); acquisition of data (KP, RS); analysis and interpretation of data (all); drafting of the manuscript (all); critical revision of the manuscript for important intellectual content (SS); statistical analysis (not applicable); obtained funding (not applicable); administrative, technical, or material support; study supervision (SS).

Corresponding author

Correspondence toSammy Saab.

Ethics declarations

Conflict of interest

SS is on the speaker bureau for Gilead Pharmaceuticals, AbbVie, Takeda, Salix, Ipsen, Madrigal, Mallinckrodt. He works as a consultant for Gilead, Ipsen, Cymabay, Madrigal, Mallinckrodt.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Cite this article

Pak, K., Sachar, R. & Saab, S. Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States.Dig Dis Sci 70, 1547–1554 (2025). https://doi.org/10.1007/s10620-025-08909-z

Download citation

Keywords